NIMOTOP
Description
NIMOTOP
Composition:
1 bottle with 50ml of soln for infusion contains 10mg nimodipine in 50mL of alcoholic solvent.
Active ingredient: Ethanol 96%, macrogol 400, sodium dicitrate, anhydrous citric acid, water to inj.
Therapeutic Action:
Hypotensive and vasodilator of complex action.
Administration:
Soln. for IV infusion.
Indications:
Prophylaxis and treatment of ischemic neurological deterioration produced by cerebral vasospasm after subarachnoid hemorrhage of aneurysmal origin.
Posology:
- IV infusion: Start 1mg Nimodipine (-5mL Nimotop solution for infusion / h) for 2 h (approx. 15 µg / kg body weight / h). If the dose is well tolerated and in particular, if a significant drop in blood pressure is not observed, the dose should be increased to 2 mg / h of nimodipine (= 10 ml of nimodipine, solution for infusion / h) (approx. 30 µg / kg body weight / h) after 2 hours. Patients who weigh significantly less than 70 kg or who have a labile blood pressure should initiate treatment with a dose of 0.5 mg / h of nimodipine (= 2.5 ml of nimodipine, solution for infusion / h).
- Intracisternal instillation: During surgery, a freshly prepared, diluted solution of nimodipine (1 ml of nimodipine, solution for infusion plus 19 ml of Ringer’s solution), warmed up to blood temperature, can be instilled intracisternally. This diluted nimodipine solution should be used immediately after preparation. This medicine should be administered with caution in patients with mild to moderate hepatic impairment. Nimotop should be administered with caution in patients with severe renal impairment (creatinine clearance <20 ml / min).
- Administration: Nimodipine, solution for infusion, is administered as an IV infusion. continues with a pump through a central catheter. It is applied through a 3-way stopcock together with a solution of 5% glucose, 0.9% sodium chloride, lactated Ringer, magnesium lactated Ringer, dextran 40 or (poly (O-2-hydroxyethyl ) 6% starch, in an approximate 1: 4 ratio (nimodipine: co-infusion). Mannitol, human albumin and blood are also suitable for co-infusion. The 3-step faucet will be used to connect the polyethylene tubing with the nimodipine to the co-infusion line and central catheter. Nimodipine solution should not be added to any infusion bag or bottle or mixed with other medications. Administration of nimodipine will be continued during anesthesia, surgery, and angiography.
Precaution:
Patients with severe kidney, cardiovascular, liver disorders; hypotensive patients. Very elderly patients with multiple morbidity. If the water content in brain tissue is high or if there is marked intracranial hypertension.
As the active ingredient in the product is absorbed by polyvinyl chloride (PVC), only polyethylene (PE) infusion tubes should be used.
Administration of Nimotop IV undiluted adequately increases the risk of phlebitis.
Presentation:
Nimotop is presented in a 50mL bottle.
E.F. 24,278
Manufacturer:
Bayer.
Reviews
There are no reviews yet.